Moderna
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-01-01
- Employees
- 5.6K
- Market Cap
- $30.3B
- Website
- http://www.modernatx.com
- Introduction
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States
- Conditions
- SARS-CoV-2
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 50000000
- Registration Number
- NCT04958954
- Locations
- 🇺🇸
Aetion Inc., New York, New York, United States
Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome Study
- Conditions
- SARS-CoV-2
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04958304
- Locations
- 🇺🇸
IQVIA Call Center for United States and Canada, Durham, North Carolina, United States
A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults
- Conditions
- Seasonal Influenza
- Interventions
- Biological: mRNA-1010Biological: PlaceboBiological: Active Comparator
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 885
- Registration Number
- NCT04956575
- Locations
- 🇺🇸
Research Centers of America - ERGG - PPDS, Hollywood, Florida, United States
🇺🇸Alliance for Multispecialty Research, LLC - Phoenix, Tempe, Arizona, United States
🇺🇸Meridian Clinical Research (Savannah Georgia) - Platinum - PPDS, Savannah, Georgia, United States
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Biological: COVID-19 Vaccine
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 8538
- Registration Number
- NCT04941144
- Locations
- 🇯🇵
Moderna selected site, Tokyo, Japan
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273.213Biological: mRNA-1273.529Biological: mRNA-1273.617.2Biological: mRNA-1273.214Biological: mRNA-1273Biological: mRNA-1273.211Biological: mRNA-1273.222Biological: mRNA-1273.815Biological: mRNA-1273.231
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 5404
- Registration Number
- NCT04927065
- Locations
- 🇺🇸
Research Centers of America, Hollywood, Florida, United States
🇺🇸Jacksonville Center For Clinical Research, Jacksonville, Florida, United States
🇺🇸Meridian Clinical Research (Iowa), Sioux City, Iowa, United States
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
- Conditions
- Zika Virus
- Interventions
- Biological: mRNA-1893Biological: Placebo
- First Posted Date
- 2021-06-08
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 808
- Registration Number
- NCT04917861
- Locations
- 🇵🇷
Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico
🇵🇷Ponce Medical School Foundation, Inc., Ponce, Puerto Rico
🇵🇷Carribean Medical Research, San Juan, Puerto Rico
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
- Conditions
- Healthy Volunteers
- Interventions
- Drug: mRNA-6231
- First Posted Date
- 2021-06-07
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04916431
- Locations
- 🇦🇺
Nucleus Network Limited, Melbourne, Victoria, Australia
A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT04899310
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1273
- First Posted Date
- 2021-04-26
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT04860297
- Locations
- 🇺🇸
Aventiv Research Inc, Mesa, Arizona, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
- Conditions
- SARS-CoV-2
- Interventions
- Biological: mRNA-1283Biological: mRNA-1273Biological: Placebo
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- ModernaTX, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT04813796
- Locations
- 🇺🇸
Synexus Clinical Research US Phoenix Southeast, Inc., Chandler, Arizona, United States
🇺🇸Optimal Research San Diego, LLC, San Diego, California, United States
🇺🇸Optimal Research Illinois, LLC, Peoria, Illinois, United States